Aduro Biotech Inc

Aduro Biotech — Investor Presentation (January 2020)

40 slides from Aduro Biotech's investor presentation, Jan 13, 2020

  1. Slide 1: Corporate Presentation January 2020

    Corporate Presentation January 2020 DISCOVERING & DEVELOPING THERAPIES FOR CHALLENGING DISEASES Exhibit 99.1

  2. Slide 2: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not historical facts. Th

  3. Slide 3: Developing Therapies Targeting STING & APRIL Pathways

    Developing Therapies Targeting STING & APRIL Pathways for Oncology, Autoimmune & Inflammatory Diseases Financial Strength Strategic Alliances Leaders in cGAS-STING & APRIL Pathways Co-development and co-commercialization partnership with NVS Potential near-term development milestones $235M at end of

  4. Slide 4: Aduro Pipeline

    Aduro Pipeline Indication Discovery Preclinical Phase 1 Phase 2 Current Status ADU-S100 (MIW815) Intratumoral STING Agonist Advanced/metastatic solid tumors/lymphomas Dose escalation completed No single agent expansion planned + spartalizumab (α-PD-1) Advanced/metastatic solid tumors/lymphomas Dose

  5. Slide 5: ADU-S100 (MIW815) Intratumoral STING agonist

    ADU-S100 (MIW815) Intratumoral STING agonist

  6. Slide 6: ADU-S100 (MIW815) Demonstrated Preclinical Anti-Tumor Activity

    ADU-S100 (MIW815) Demonstrated Preclinical Anti-Tumor Activity STING activation in the hematopoietic compartment drives ADU-S100 (MIW815) dependent anti-tumor immunity Type I IFN is required for optimal anti-tumor immune response ADU-S100 (MIW815) induces both local innate immune activation in injec

  7. Slide 7: ADU-S100 (MIW815) Monotherapy

    ADU-S100 (MIW815) Monotherapy

  8. Slide 8: Data Highlights from Phase 1 ADU-S100 Monotherapy Trial

    Well tolerated in heavily pre-treated, heterogenous patient population 2 of 41 patients treated had a PR, one patient received prior anti-PD-1 therapy 11 patients achieved SD Observed dose-dependent increase in IFN-ß after ADU-S100 (MIW815) administration, indicating target engagement and activation

  9. Slide 9: ADU-S100 (MIW815) + spartalizumab (α-PD-1)

    ADU-S100 (MIW815) + spartalizumab (α-PD-1)

  10. Slide 10: Preliminary Anti-tumor Activity

    Preliminary Anti-tumor Activity CRC, colorectal cancer; SCC, squamous cell carcinoma. Data cut-off: April 5, 2019 No patients achieved a response; however, six patients achieved SD Tumor types: Ovarian, breast, uveal melanoma, head and neck, and cutaneous melanoma Four of whom maintained SD for ≥6 m

  11. Slide 11: Data Highlights from Phase 1 ADU-S100 + Spartalizumab

    ADU-S100 (MIW815) + spartalizumab was generally well tolerated in patients with solid tumors or lymphomas, with no DLTs reported as of the data cut-off The MTD was not reached The combination has demonstrated anti-tumor activity in PD-1–naive TNBC and PD-1–relapsed/refractory melanoma Three out of e

  12. Slide 12: ADU-S100 (MIW815) + pembrolizumab in First-Line SCCHN

    ADU-S100 (MIW815) + pembrolizumab (α-PD-1) in First-Line SCCHN

  13. Slide 13: Phase 2 Ongoing: ADU-S100 + Pembrolizumab in First-Line SCCHN

    Phase 2 Ongoing: ADU-S100 (MIW815) + Pembrolizumab in First-Line SCCHN Shift from heavily pre-treated, heterogenous patient populations to earlier lines of treatment for patients with specific tumor type Increasing evidence that potential benefit from immunotherapies may be greater in patients with

  14. Slide 14: Phase 2 Clinical Trial Design: ADU-S100 + Pembrolizumab in SCCHN

    Phase 2 Clinical Trial Design: ADU-S100 (MIW815) + Pembrolizumab in First-Line SCCHN Treatment Period ADU-S100: Fixed dose IT injection, up to two lesions Pembrolizumab: 200 mg IV infusion Patients are treated until confirmed disease progression, unacceptable toxicity or 35 cycles Phase 2 (N=34) Pat

  15. Slide 15: ADU-S100 (MIW815) Intravesical administration in BCG-refractory NMIBC

    ADU-S100 (MIW815) Intravesical administration in BCG- refractory NMIBC

  16. Slide 16: Rationale for Intravesical ADU-S100 in NMIBC

    Rationale for Intravesical ADU-S100 in NMIBC Scientific Local, superficial disease in which local control drives disease outcome Ablation of the tumor may be sufficient to control disease, anenestic response less important Similar to BCG, ADU-S100 is a small molecule with potential to induce a local

  17. Slide 17: Bladder Cancer is a "Hot" Tumor with High TMB & Inflammatory GEP

    Bladder Cancer is a “Hot” Tumor with High TMB & Inflammatory GEP Schumacher et al. Science. 2015. High mutational burden rate for potential immunogenicity

  18. Slide 18: Scientific Rationale for ADU-S100 in BCG refractory NMIBC

    Scientific Rationale for ADU-S100 in BCG refractory NMIBC 4. Relatively high mutational burden rate, potential immunogenicity CD8+ T cell activation ADU-S100 1. BCG refractory patients have increased macrophages, S100 targets and turns on cytokine production 2. ADU-S100 is a strong innate immune sti

  19. Slide 19: ADU-S100 Activates an Immune Response in the Bladder

    ADU-S100 Activates an Immune Response in the Bladder after Intravesicular Delivery and Controls Tumors in Preclinical Models Preclinical efficacy in standard orthotopic model, MB49 bladder tumor Observe local cytokine induction with intravesicular delivery of ADU-S100 Preliminary data demonstrates a

  20. Slide 20: Major Unmet Need in BCG-Unresponsive NMIBC

    Major Unmet Need in BCG-Unresponsive NMIBC BCG treatment will eventually fail in up to 50% of patients Due to worldwide shortage, only 50% of patients who need BCG receive treatment Global Incidence of Bladder Cancer BCG-Relapsed/ Refractory Patients* Kamat, A., Flaig, T., Grossman, H. et al. Consen

  21. Slide 21: Valrubicin is the Only Approved Option for BCG Refractory CIS

    Valrubicin is the Only Approved Option for BCG Refractory CIS when Cystectomy is Not an Option and Few Ongoing Clinical Studies Single-arm study of patients with BCG failure 70% with ≥2 prior BCG courses 80% with 2 – 24 month interval between last treatment and valrubicin DFR 6 months = 21% Suboptim

  22. Slide 22: BION-1301 Anti-APRIL Antibody

    BION-1301 Anti-APRIL Antibody

  23. Slide 23: IgA Nephropathy: Biology

    IgA Nephropathy: Biology IgA nephropathy (IgAN) is a chronic autoimmune disease associated with inflammation in the kidneys that diminishes their ability to filter blood A key breakthrough was identification of IgA1 molecules lacking glycosylation at the hinge region, often referred to as galactose-

  24. Slide 24: IgA Nephropathy: Epidemiology

    IgA Nephropathy: Epidemiology IgAN is the most frequent biopsy-proven primary glomerular disease, but the geographic distribution varies widely Clinical findings that trigger biopsy vary by country Biopsy registry data underestimate disease burden as patients with mild disease may not undergo biopsy

  25. Slide 25: IgA Nephropathy: Diagnosis & Disease Progression

    IgA Nephropathy: Diagnosis & Disease Progression Diagnosis Patients often diagnosed in their 20s or 30s Disease Progression 30% to 40% of patients with IgAN progress to ESRD within approximately 20 years Diagnosis, which requires biopsy , often made following GI or respiratory infection with observa

  26. Slide 26: IgA Nephropathy: Treatment

    IgA Nephropathy: Treatment There are no approved treatments for IgAN Current standard of care treatment includes: Controlling hypertension (via renin-angiotensin blockade), which can reduce proteinurea and slow disease progression Immunosuppressive drugs (e.g., corticosteroids for 6 months), which h

  27. Slide 27: APRIL and its Role in IgAN

    APRIL and its Role in IgAN A Proliferation Inducing Ligand, or APRIL: TNF-family ligand implicated in regulation of B cell-mediated immune responses Soluble factor that functions via binding to TACI and BCMA receptors Critically drives IgA class switching through TACI Survival of IgA-producing plasm

  28. Slide 28: APRIL Pathway Agents Uniquely Positioned in Hit Hypothesis

    APRIL Pathway Agents Uniquely Positioned in 4 Hit Hypothesis on the Pathogenesis of IgA Nephropathy BION-1301 should impact all four categories of IgAN pathogenesis, and in the future could potentially be used in combination with drugs that have different MOAs α-APRIL α-APRIL α-APRIL α-APRIL α-Compl

  29. Slide 29: BION-1301: First-in-Class Fully Blocking Anti-APRIL Antibody

    BION-1301: First-in-Class Fully Blocking Anti-APRIL Antibody First-in-class monoclonal antibody blocking APRIL binding to both of its natural ligands, the BCMA and TACI receptors No toxicology findings observed in 1-month toxicology study Well-tolerated in clinical studies (NCT03340883, NCT03945318)

  30. Slide 30: Human IgA+ Plasma Cells Express High TACI and BCMA Levels

    Human IgA+ Plasma Cells Express High TACI and BCMA Levels and Depend on APRIL for Survival and IgA production In vitro-generated IgA+ plasma cells selectively express high BCMA and TACI In vitro-generated IgA+ plasma cells require APRIL to survive and produce IgA Anti-APRIL (.01A) inhibits plasma ce

  31. Slide 31: Preclinical Data in Mouse Models Provide Rationale for BION-1301

    Preclinical Data in Mouse Models Provide Compelling Rationale for BION-1301 in IgA Nephropathy Increased IgA production seen in hAPRIL Tg mice The BION-1301 parental antibody hAPRIL.01A inhibits IgA production in hAPRIL Tg mice Treatment with anti-APRIL mAb 4540 suppresses proteinuria in IgAN ddY mi

  32. Slide 32: Preclinical Data from Tox Studies in Non-Human Primates

    Preclinical Data from Tox Studies in Non-Human Primates (NHPs) Provide Compelling Rationale for BION-1301 in IgA Nephropathy BION-1301 Reduces Serum IgA, IgG and IgM levels in NHPs BION-1301 Dose Response in NHPs Dulos J, et al. ASH 2017 poster presentation: abstract 1827.

  33. Slide 33: Phase 1 Study of BION-1301 in Healthy Volunteers & IgAN Patients

    Phase 1 Study of BION-1301 in Healthy Volunteers & IgA Nephropathy Patients Ongoing Up to 5 Dose Cohorts Part 1 in Healthy Volunteers: Double-blind, Placebo-controlled, Single Ascending Dose 3 Dose Cohorts Part 2 in Healthy Volunteers: Double-blind, Placebo-controlled, Multiple Ascending Dose Part 3

  34. Slide 34: FDA Co-Authored Article Supporting Proteinuria as Surrogate Endpoint

    FDA Co-Authored Article Supporting Reduction in Proteinuria as a Surrogate Endpoint for eGFR for Accelerated Approval Proteinuria As of January 2019, FDA officially agrees to proteinuria as surrogate endpoint for eGFR in IgA Nephropathy Expect other global health authorities to follow suit General c

  35. Slide 35: Several Ongoing Toxicology Studies to Support Subcutaneous Dosing

    Several Ongoing Toxicology Studies to Support Long-Term Subcutaneous Dosing 1-Month intravenous (IV) toxicology study completed prior to IND filing No tox findings noted 1-Month subcutaneous (SC) local tolerability toxicology study completed Will support initiation of Phase 1 IV/SC bridging study in

  36. Slide 36: Business Overview

    Business Overview

  37. Slide 37: Aduro Strategic Collaborations and Partnerships

    Aduro Strategic Collaborations and Partnerships ADU-S100 and other STING agonists cGAS-STING pathway inhibitor program Anti-CD27 agonist Oncology Autoimmune & Inflammatory Oncology $700M upfront & potential milestones $50M equity Co-development & co-commercialization $12M upfront $620M potential dev

  38. Slide 38: Strong Financial Position and Broad Intellectual Property Portfolio

    Strong Financial Position and Broad Intellectual Property Portfolio Q3 2019 Financials Cash, cash equivalents and marketable securities $235.4M R&D expenses $15.5M G&A expenses $8.7M Shares outstanding as of September 30, 2019 80.5M Extensive Patent Portfolio Global Rights (includes in-licensed pate

  39. Slide 39: Potential Upcoming Catalysts

    Potential Upcoming Catalysts Indication Catalyst H1 2020 H2 2020 ADU-S100 (MIW815) Intratumoral STING Agonist + spartalizumab (α-PD-1) Advanced/metastatic solid tumors or lymphomas Report complete Ph 1 dose escalation & enrichment results + pembrolizumab (α-PD-1) 1st-line SCCHN Report interim study

  40. Slide 40: Slide 40

Aduro Biotech — Investor Presentation (January 2020) on 6ix